Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study.
Vaccine
; 21(17-18): 2133-44, 2003 May 16.
Article
en En
| MEDLINE
| ID: mdl-12706704
ABSTRACT
We assessed whether trivalent live, cold-adapted influenza virus (CAIV-T) vaccine provides added protection when co-administered with trivalent inactivated influenza virus vaccine (TVV) in patients with chronic obstructive pulmonary disease (COPD). Subjects (N=2215) were randomly assigned to receive either TVV intramuscularly (IM) and CAIV-T intranasally (TC), or TVV and placebo (TP). The vaccines were well-tolerated. Efficacy of TC compared to TP was not statistically significant and was 0.16 for any influenza virus strain (95% confidence limit (CL) -0.22, 0.43), 0.26 for A (H3N2) virus (95% CL -0.17, 0.53), and -0.05 for type B virus (95% CL -1.13, 0.48). However, there was a possible advantage for TC over TP in reducing respiratory consequences of an influenza season measured by pulmonary function and symptoms at end of study.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Vacunas contra la Influenza
/
Vacunas de Productos Inactivados
/
Enfermedad Pulmonar Obstructiva Crónica
/
Gripe Humana
Tipo de estudio:
Clinical_trials
Límite:
Aged
/
Humans
/
Middle aged
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Vaccine
Año:
2003
Tipo del documento:
Article
País de afiliación:
Estados Unidos